About cadrenal therapeutics inc - CVKD
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
CVKD At a Glance
Cadrenal Therapeutics, Inc.
822 A1A North
Ponte Vedra Beach, Florida 32082
| Phone | 1-904-300-0701 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -13,237,362.00 | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CVKD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.788 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.707 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
CVKD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,647,472.40 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CVKD Liquidity
| Current Ratio | 2.653 |
| Quick Ratio | 2.653 |
| Cash Ratio | 2.524 |
CVKD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -183.213 |
| Return on Equity | -260.109 |
| Return on Total Capital | -483.34 |
| Return on Invested Capital | -260.109 |
CVKD Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |